HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The use of neutrophil elastase inhibitor in the treatment of acute lung injury after pneumonectomy.

AbstractBACKGROUND:
The prognosis of acute lung injury (ALI) after pneumonectomy is poor, with reported mortality rates of 30-100%. Neutrophil elastase inhibitor (NEI) is known to prevent lung injury caused by neutrophil elastase and improve lung function in ALI. We evaluated the effect of NEI on ALI after pneumonectomy.
METHODS:
We analyzed nine patients who required ventilator care due to ALI after pneumonectomy. Five of these patients underwent conventional ventilator care (group I), and four patients underwent ventilator care and were administrated NEI (group II). We retrospectively analyzed the lung injury score (LIS) for 10 days after intubation.
RESULTS:
The LIS before intubation satisfied the diagnostic criteria of ALI or acute respiratory distress syndrome (ARDS) in all patients. After intubation, the LIS improved in both groups. But, as times went on, the mean value of the LIS in group II was lower compared to group I. In group I, only one patient underwent extubation. In group II, extubation was possible in three patients. Mortality rates were 80% in group I and 25% in group II.
CONCLUSIONS:
We conclude that NEI may improve the lung function, shorten the duration of mechanical ventilation, and reduce mortality in patients with ALI after pneumonectomy.
AuthorsSang Kwon Lee, Bong Soo Son, Jung Joo Hwang, Kil Dong Kim, Do Hyung Kim
JournalJournal of cardiothoracic surgery (J Cardiothorac Surg) Vol. 8 Pg. 69 (Apr 08 2013) ISSN: 1749-8090 [Electronic] England
PMID23566653 (Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Proteinase Inhibitory Proteins, Secretory
  • Sulfonamides
  • sivelestat
  • Glycine
Topics
  • Acute Lung Injury (drug therapy, etiology, mortality, therapy)
  • Adult
  • Aged
  • Combined Modality Therapy
  • Drug Administration Schedule
  • Glycine (analogs & derivatives, therapeutic use)
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Pneumonectomy
  • Postoperative Complications (drug therapy, mortality, therapy)
  • Proteinase Inhibitory Proteins, Secretory (therapeutic use)
  • Respiration, Artificial
  • Respiratory Distress Syndrome (drug therapy, etiology, mortality, therapy)
  • Retrospective Studies
  • Sulfonamides (therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: